New approaches to prophylactic human papillomavirus vaccines for cervical cancer prevention

Antiviral Therapy

Volumn 17, Issue 3, 2012, Pages 425-434

  Gersch, Elizabeth D ^a   Gissmann, Lutz ^b,c   Garcea, Robert L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VECTOR; CAPSID PROTEIN L1; CAPSID PROTEIN L2; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR; WART VIRUS VACCINE;

ADENO ASSOCIATED VIRUS; ANTIBODY TITER; BACILLUS; CANCER INCIDENCE; COST CONTROL; DEVELOPING COUNTRY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; FREEZING; GENE EXPRESSION SYSTEM; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNE RESPONSE; INSECT CELL; LISTERIA MONOCYTOGENES; MEASLES VIRUS; NONHUMAN; PICORNAVIRUS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REVIEW; SALMONELLA; TRANSGENIC PLANT; UTERINE CERVIX CANCER; VESICULAR STOMATITIS VIRUS; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; VIRUS TYPING; WART VIRUS;

BACTERIA; CAPSID PROTEINS; DRUG DESIGN; FEMALE; GENETIC VECTORS; HUMANS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UTERINE CERVICAL NEOPLASMS; VACCINES, DNA; VIRUSES;

EID: 84861680250     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1941     Document Type: Review

References (85)

1. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers in the world. Summary Report 2010. (Updated 15 November 2010. Accessed 11 March 2011.) Available from http://apps.who.int/hpvcentre/statistics/ dynamic/ico/country-pdf/XWX.pdf?CFID= 4804166&CFTOKEN=32983136
2. Cohen J. Public health. High hopes and dilemmas for a cervical cancer vaccine. Science 2005; 308:618-621. (Pubitemid 40594357)
3. Muñoz N, Bosch FX, Castellsague X, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111:278-285. (Pubitemid 38924707)
4. Roldão A, Mellado MC, Castilho LR, Carrondo MJ, Alves PM. Virus-like particles in vaccine development. Expert Rev Vaccines 2010; 9:1149-1176.
5. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367:1247-1255.
6. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006; 95:1459-1466. (Pubitemid 44863348)
7. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010; 28:6247-6255.
8. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007; 298:743-753. (Pubitemid 47263157)
9. Schiller JT, Lowy DR. Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials. J Infect Dis 2009; 200:166-171.
10. Kwak K, Yemelyanova A, Roden RB. Prevention of cancer by prophylactic human papillomavirus vaccines. Curr Opin Immunol 2011; 23:244-251.
11. Day PM, Kines RC, Thompson CD, et al. In vivo mechanisms of vaccine-induced protection against HPV infection. Cell Host Microbe 2010; 8:260-270.
12. Roberts JN, Buck CB, Thompson CD, et al. Genital transmission of HPV in a mouse model is potentiated by nonoxynol-9 and inhibited by carrageenan. Nat Med 2007; 13:857-861. (Pubitemid 47038188)
13. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374:301-314.
14. Buck CB, Cheng N, Thompson CD, et al. Arrangement of L2 within the papillomavirus capsid. J Virol 2008; 82:5190-5197. (Pubitemid 351705228)
15. Finnen RL, Erickson KD, Chen XS, Garcea RL. Interactions between papillomavirus L1 and L2 capsid proteins. J Virol 2003; 77:4818-4826. (Pubitemid 36402831)
16. Breitburd F, Kirnbauer R, Hubbert NL, et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69:3959-3963.
17. Christensen ND, Kreider JW. Antibody-mediated neutralization in vivo of infectious papillomaviruses. J Virol 1990; 64:3151-3156. (Pubitemid 20219515)
18. Rose RC, White WI, Li M, et al. Human papillomavirus type 11 recombinant L1 capsomeres induce virusneutralizing antibodies. J Virol 1998; 72:6151-6154. (Pubitemid 28283406)
19. Fligge C, Giroglou T, Streeck RE, Sapp M. Induction of type-specific neutralizing antibodies by capsomeres of human papillomavirus type 33. Virology 2001; 283:353-357. (Pubitemid 32881182)
20. Yuan H, Estes PA, Chen Y, et al. Immunization with a pentameric L1 fusion protein protects against papillomavirus infection. J Virol 2001; 75:7848-7853. (Pubitemid 32743655)
21. Ohlschläger P, Osen W, Dell K, et al. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice. J Virol 2003; 77:4635-4645. (Pubitemid 36402813)
22. Thönes N, Muller M. Oral immunization with different assembly forms of the HPV 16 major capsid protein L1 induces neutralizing antibodies and cytotoxic T-lymphocytes. Virology 2007; 369:375-388. (Pubitemid 350087191)
23. Stahl-Hennig C, Eisenblatter M, Jasny E, et al. Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 2009; 5:e1000373.
24. Chen XS, Casini G, Harrison SC, Garcea RL. Papillomavirus capsid protein expression in Escherichia coli: purification and assembly of HPV11 and HPV16 L1. J Mol Biol 2001; 307:173-182. (Pubitemid 33029974)
25. Schädlich L, Senger T, Kirschning CJ, Muller M, Gissmann L. Refining HPV 16 L1 purification from E. coli: reducing endotoxin contaminations and their impact on immunogenicity. Vaccine 2009; 27:1511-1522.
26. Kohl TO, Hitzeroth II, Christensen ND, Rybicki EP. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum. BMC Biotechnol 2007; 7:56.
27. Regnard GL, Halley-Stott RP, Tanzer FL, Hitzeroth II, Rybicki EP. High level protein expression in plants through the use of a novel autonomously replicating geminivirus shuttle vector. Plant Biotechnol J 2010; 8:38-46.
28. Varsani A, Williamson AL, Stewart D, Rybicki EP. Transient expression of human papillomavirus type 16 L1 protein in Nicotiana benthamiana using an infectious tobamovirus vector. Virus Res 2006; 120:91-96. (Pubitemid 43947302)
29. Waheed MT, Thones N, Muller M, et al. Transplastomic expression of a modified human papillomavirus L1 protein leading to the assembly of capsomeres in tobacco: a step towards cost-effective second-generation vaccines. Transgenic Res 2011; 20:271-282.
30. Warzecha H, Mason HS, Lane C, et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003; 77:8702-8711. (Pubitemid 36936081)
31. Lenzi P, Scotti N, Alagna F, et al. Translational fusion of chloroplast-expressed human papillomavirus type 16 L1 capsid protein enhances antigen accumulation in transplastomic tobacco. Transgenic Res 2008; 17:1091-1102.
32. Maclean J, Koekemoer M, Olivier AJ, et al. Optimization of human papillomavirus type 16 (HPV-16) L1 expression in plants: comparison of the suitability of different HPV-16 L1 gene variants and different cell-compartment localization. J Gen Virol 2007; 88:1460-1469. (Pubitemid 46723227)
33. Zheng J, Yang X, Sun Y, Lai B, Wang Y. Stable high-level expression of truncated human papillomavirus type 16 L1 protein in Drosophila Schneider-2 cells. Acta Biochim Biophys Sin (Shanghai) 2008; 40:437-442. (Pubitemid 351704047)
34. Senger T, Schadlich L, Gissmann L, Muller M. Enhanced papillomavirus-like particle production in insect cells. Virology 2009; 388:344-353.
35. Cortes-Perez NG, Kharrat P, Langella P, Bermudez-Humaran LG. Heterologous production of human papillomavirus type-16 L1 protein by a lactic acid bacterium. BMC Res Notes 2009; 2:167.
36. Aires KA, Cianciarullo AM, Carneiro SM, et al. Production of human papillomavirus type 16 L1 virus-like particles by recombinant Lactobacillus casei cells. Appl Environ Microbiol 2006; 72:745-752.
37. Cho HJ, Shin HJ, Han IK, et al. Induction of mucosal and systemic immune responses following oral immunization of mice with Lactococcus lactis expressing human papillomavirus type 16 L1. Vaccine 2007; 25:8049-8057.
38. Bazan SB, de Alencar Muniz Chaves A, Aires KA, et al. Expression and characterization of HPV-16 L1 capsid protein in Pichia pastoris. Arch Virol 2009; 154:1609-1617.
39. Park MA, Kim HJ. Optimum conditions for production and purification of human papillomavirus type 16 L1 protein from Saccharomyces cerevisiae. Protein Expr Purif 2008; 59:175-181.
40. Kim SN, Jeong HS, Park SN, Kim HJ. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae. J Virol Methods 2007; 139:24-30. (Pubitemid 44872904)
41. Sasagawa T, Tani M, Basha W, et al. A human papillomavirus type 16 vaccine by oral delivery of L1 protein. Virus Res 2005; 110:81-90. (Pubitemid 40544549)
42. Millán AF, Gõmez-Sebastian S, Nuñez MC, Veramendi J, Escribano JM. Human papillomavirus-like particles vaccine efficiently produced in a non-fermentative system based on insect larva. Protein Expr Purif 2010; 74:1-8.
43. Cantarella G, Liniger M, Zuniga A, et al. Recombinant measles virus-HPV vaccine candidates for prevention of cervical carcinoma. Vaccine 2009; 27:3385-3390.
44. Baud D, Ponci F, Bobst M, De Grandi P, Nardelli-Haefliger D. Improved efficiency of a Salmonella-based vaccine against human papillomavirus type 16 virus-like particles achieved by using a codon-optimized version of L1. J Virol 2004; 78:12901-12909. (Pubitemid 39507798)
45. Echchannaoui H, Bianchi M, Baud D, et al. Intravaginal immunization of mice with recombinant Salmonella enterica serovar Typhimurium expressing human papillomavirus type 16 antigens as a potential route of vaccination against cervical cancer. Infect Immun 2008; 76:1940-1951. (Pubitemid 351656127)
46. Fraillery D, Baud D, Pang SY, et al. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Clin Vaccine Immunol 2007; 14:1285-1295. (Pubitemid 350012970)
47. van Kuppeveld FJ, de Jong A, Dijkman HB, Andino R, Melchers WJ. Studies towards the potential of poliovirus as a vector for the expression of HPV 16 virus-like-particles. FEMS Immunol Med Microbiol 2002; 34:201-208. (Pubitemid 35335520)
48. Roberts A, Reuter JD, Wilson JH, Baldwin S, Rose JK. Complete protection from papillomavirus challenge after a single vaccination with a vesicular stomatitis virus vector expressing high levels of L1 protein. J Virol 2004; 78:3196-3199. (Pubitemid 38314381)
49. Liu DW, Chang JL, Tsao YP, et al. Co-vaccination with adeno-associated virus vectors encoding human papillomavirus 16 L1 proteins and adenovirus encoding murine GM-CSF can elicit strong and prolonged neutralizing antibody. Int J Cancer 2005; 113:93-100.
50. Kuck D, Lau T, Leuchs B, et al. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1. J Virol 2006; 80:2621-2630. (Pubitemid 43346358)
51. Nieto K, Kern A, Leuchs B, et al. Combined prophylactic and therapeutic intranasal vaccination against human papillomavirus type-16 using different adeno-associated virus serotype vectors. Antivir Ther 2009; 14:1125-1137.
52. Jabbar IA, Fernando GJ, Saunders N, et al. Immune responses induced by BCG recombinant for human papillomavirus L1 and E7 proteins. Vaccine 2000; 18:2444-2453. (Pubitemid 30156816)
53. Govan VA, Christensen ND, Berkower C, Jacobs WR, Jr., Williamson AL. Immunisation with recombinant BCG expressing the cottontail rabbit papillomavirus (CRPV) L1 gene provides protection from CRPV challenge. Vaccine 2006; 24:2087-2093. (Pubitemid 43255151)
54. Yang XF, Qu XZ, Wang K, et al. Construction of prophylactic human papillomavirus type 16 L1 capsid protein vaccine delivered by live attenuated Shigella flexneri strain sh42. Acta Biochim Biophys Sin (Shanghai) 2005; 37:743-750. (Pubitemid 44890984)
55. Li W, Liu H, Yang X, et al. Development of prophylactic recombinant HPV58-attenuated Shigella live vector vaccine and evaluation of its protective efficacy and immunogenicity in the guinea pig keratoconjunctivitis model. Acta Biochim Biophys Sin (Shanghai) 2009; 41:137-145.
56. Mustafa W, Maciag PC, Pan ZK, et al. Listeria monocytogenes delivery of HPV-16 major capsid protein L1 induces systemic and mucosal cell-mediated CD4+ and CD8+ T-cell responses after oral immunization. Viral Immunol 2009; 22:195-204.
57. Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009; 199:926-935.
58. Smith JF, Brownlow M, Brown M, et al. Antibodies from women immunized with Gardasil cross-neutralize HPV 45 pseudovirions. Hum Vaccin 2007; 3:109-115. (Pubitemid 47501028)
59. Kemp TJ, Hildesheim A, Safaeian M, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011; 29:2011-2014.
60. Bosch FX, Burchell AN, Schiffman M, et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008; 26 Suppl 10:K1-K16.
61. Merck. Merck Pipeline. (Updated 16 February 2011. Accessed 13 April 2011.) Available from http://www.merck.com/research/pipeline/home.html
62. WHO/ICO Information Centre on HPV and Cervical Cancer (HPV Information Centre). Human papillomavirus and related cancers, fact sheets 2010. (Updated 15 September 2010. Accessed 11 March 2011.) Available from http://apps.who.int/ hpvcentre/statistics/dynamic/ico/SummaryReportsSelect.cfm
63. Gambhira R, Karanam B, Jagu S, et al. A protective and broadly cross-neutralizing epitope of human papillomavirus L2. J Virol 2007; 81:13927-13931. (Pubitemid 350247886)
64. Kondo K, Ishii Y, Ochi H, et al. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 2007; 358:266-272. (Pubitemid 46136425)
65. Gambhira R, Jagu S, Karanam B, et al. Protection of rabbits against challenge with rabbit papillomaviruses by immunization with the N terminus of human papillomavirus type 16 minor capsid antigen L2. J Virol 2007; 81:11585-11592. (Pubitemid 47623790)
66. Campo MS, O'Neil BW, Grindlay GJ, et al. A peptide encoding a B-cell epitope from the N-terminus of the capsid protein L2 of bovine papillomavirus-4 prevents disease. Virology 1997; 234:261-266. (Pubitemid 27360117)
67. Chandrachud LM, Grindlay GJ, McGarvie GM, et al. Vaccination of cattle with the N-terminus of L2 is necessary and sufficient for preventing infection by bovine papillomavirus-4. Virology 1995; 211:204-208.
68. Embers ME, Budgeon LR, Pickel M, Christensen ND. Protective immunity to rabbit oral and cutaneous papillomaviruses by immunization with short peptides of L2, the minor capsid protein. J Virol 2002; 76:9798-9805. (Pubitemid 35006520)
69. Gaukroger JM, Chandrachud LM, O'Neil BW, et al. Vaccination of cattle with bovine papillomavirus type 4 L2 elicits the production of virus-neutralizing antibodies. J Gen Virol 1996; 77:1577-1583. (Pubitemid 26248674)
70. Day PM, Gambhira R, Roden RB, Lowy DR, Schiller JT. Mechanisms of human papillomavirus type 16 neutralization by L2 cross-neutralizing and L1 type-specific antibodies. J Virol 2008; 82:4638-4646. (Pubitemid 351563700)
71. Jagu S, Karanam B, Gambhira R, et al. Concatenated multitype L2 fusion proteins as candidate prophylactic panhuman papillomavirus vaccines. J Natl Cancer Inst 2009; 101:782-792.
72. Alphs HH, Gambhira R, Karanam B, et al. Protection against heterologous human papillomavirus challenge by a synthetic lipopeptide vaccine containing a broadly cross-neutralizing epitope of L2. Proc Natl Acad Sci U S A 2008; 105:5850-5855. (Pubitemid 351758461)
73. Hitzeroth II, Passmore JA, Shephard E, et al. Immunogenicity of an HPV-16 L2 DNA vaccine. Vaccine 2009; 27:6432-6434.
74. Kim D, Gambhira R, Karanam B, et al. Generation and characterization of a preventive and therapeutic HPV DNA vaccine. Vaccine 2008; 26:351-360.
75. Rubio I, Bolchi A, Moretto N, et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 L2 (20-38) peptide displayed on bacterial thioredoxin. Vaccine 2009; 27:1949-1956.
76. Jagu S, Kwak K, Garcea RL, Roden RB. Vaccination with multimeric L2 fusion protein and L1 VLP or capsomeres to broaden protection against HPV infection. Vaccine 2010; 28:4478-4486.
77. Schellenbacher C, Roden R, Kirnbauer R. Chimeric L1-L2 virus-like particles as potential broad-spectrum human papillomavirus vaccines. J Virol 2009; 83:10085-10095.
78. Combelas N, Saussereau E, Fleury MJ, et al. Papillomavirus pseudovirions packaged with the L2 gene induce cross-neutralizing antibodies. J Transl Med 2010; 8:28.
79. do Carmo Caldeira J, Medford A, Kines RC, et al. Immunogenic display of diverse peptides, including a broadly cross-type neutralizing human papillomavirus L2 epitope, on virus-like particles of the RNA bacteriophage PP7. Vaccine 2010; 28:4384-4393.
80. Johansson EL, Wassen L, Holmgren J, Jertborn M, Rudin A. Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 2001; 69:7481-7486. (Pubitemid 33086573)
81. Nardelli-Haefliger D, Lurati F, Wirthner D, et al. Immune responses induced by lower airway mucosal immunisation with a human papillomavirus type 16 virus-like particle vaccine. Vaccine 2005; 23:3634-3641. (Pubitemid 40692408)
82. Revaz V, Zurbriggen R, Moser C, et al. Humoral and cellular immune responses to airway immunization of mice with human papillomavirus type 16 virus-like particles and mucosal adjuvants. Antiviral Res 2007; 76:75-85. (Pubitemid 47176696)
83. Balmelli C, Roden R, Potts A, et al. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72:8220-8229. (Pubitemid 28421819)
84. Reuter JD, Vivas-Gonzalez BE, Gomez D, et al. Intranasal vaccination with a recombinant vesicular stomatitis virus expressing cottontail rabbit papillomavirus L1 protein provides complete protection against papillomavirus-induced disease. J Virol 2002; 76:8900-8909. (Pubitemid 34864084)
85. Kawana K, Kawana Y, Yoshikawa H, et al. Nasal immunization of mice with peptide having a crossneutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies. Vaccine 2001; 19:1496-1502. (Pubitemid 32332735)